Your browser doesn't support javascript.
loading
Effects of treatment for diabetes mellitus on testosterone concentrations: A systematic review.
Van Cauwenberghe, Jolijn; De Block, Christophe; Vanderschueren, Dirk; Antonio, Leen.
Afiliação
  • Van Cauwenberghe J; Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, University of Antwerp, Edegem, Belgium.
  • De Block C; University of Antwerp, Faculty of Medicine and Health Sciences, Laboratory of Experimental Medicine and Paediatrics (LEMP), Wilrijk, Belgium.
  • Vanderschueren D; Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, University of Antwerp, Edegem, Belgium.
  • Antonio L; University of Antwerp, Faculty of Medicine and Health Sciences, Laboratory of Experimental Medicine and Paediatrics (LEMP), Wilrijk, Belgium.
Andrology ; 11(2): 225-233, 2023 02.
Article em En | MEDLINE | ID: mdl-36251281
ABSTRACT

BACKGROUND:

Low testosterone levels are frequently present in men with obesity and insulin resistance. Currently available treatment options (testosterone replacement therapy or lifestyle changes) hold possible risks or are insufficient. Since low testosterone levels are closely related to obesity and type 2 diabetes, treatment modalities for these conditions could result into improvement of testosterone levels.

OBJECTIVES:

To summarize the available evidence on the effects of traditional and recent treatment modalities for diabetes mellitus on testosterone levels and androgen-deficiency-related signs and symptoms. MATERIALS AND

METHODS:

PubMed was searched from the year 2000 till present using MESH terms "hypogonadism," "testosterone," "testosterone deficiency," "functional hypogonadism," and the different classes of medications. Studies with observational and experimental designs on humans that evaluated the effect of antidiabetic medications on gonadotropins and testosterone were eligible for inclusion.

RESULTS:

Current available data show no or only limited improvement on testosterone levels with the classic antidiabetic drugs. Studies with GLP1-receptor analogues show beneficial effects on both body weight and testosterone levels in men with low testosterone levels and obesity with or without type 2 diabetes. However, data are limited to small and heterogeneous study groups and only few studies report data about impact on androgen-deficiency-related signs and symptoms. DISCUSSION AND

CONCLUSION:

With the recent advances in the knowledge of the pathophysiological pathways in obesity, there is an enormous progress in the development of medications for obesity and type 2 diabetes. Newer incretin-based agents have a great potential for the treatment of functional hypogonadism due to obesity since they show promising weight reducing results. However, before the use of GLP1-receptor analogues can be suggested to treat functional hypogonadism, further studies are needed.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Testosterona / Diabetes Mellitus Tipo 2 / Eunuquismo / Hipoglicemiantes Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Testosterona / Diabetes Mellitus Tipo 2 / Eunuquismo / Hipoglicemiantes Idioma: En Ano de publicação: 2023 Tipo de documento: Article